Relationship between the expression of ERCC-1, survivin and both efficiency and prognosis of cisplatin contained first-line chemotherapy in advanced lung adenocarcinoma
- First Online:
- Cite this article as:
- Chen, X., Luo, S., Li, N. et al. Chin. -Ger. J. Clin. Oncol. (2009) 8: 265. doi:10.1007/s10330-009-0043-5
- 22 Downloads
We analyzed the relationship between the expression of ERCC-1 (excisition repair cross complement-1), survivin and sensitivity and prognosis of cisplatin contained regimens first-line chemotherapy in advanced lung adenocarcinoma.
Immunohistochemical (IHC) method was used to evaluate the expression of ERCC-1 and survivin in 80 pathologically confirmed advanced lung adenocarcinoma patients given cisplatin-contained regimens first-line chemotherapy. The response rate and survival time were analyzed according to the expression of ERCC-1 and survivin.
Only 77 patients could be reviewed by IHC staining. The expression rates of ERCC-1 and survivin were 33.77% and 53.25 % respectively. The worse response rate and shorter TTP/ PFS could be identified in ERCC-1 positive group. Patients with positive expression of survivin had worse survival time.
Expression of ERCC-1 may be a molecular marker of cisplatincontained regimens first-line chemotherapy resistance and poor prognosis in advanced lung adenocarcinoma patients. Positive expression of survivin predicates poor prognosis for patients with advanced lung adenocarcinoma.
Key wordslung adenocarcinoma ERCC-1 survivin cisplatin
Unable to display preview. Download preview PDF.